Fight Aging!

Every field of specialist knowledge consists of a series of concentric circles, the greatest knowledge at the center, the scientists advancing the state of the art, and the least knowledge at the outskirts, the public at large. In between we find lesser scientists, patient advocates, laypeople with a strong interest in the field, and so forth - various gradations of knowledge. The members of any given ring engage in an educational dialog with the next ring out, and themselves learn from the education efforts of the more knowledgeable neighboring inner ring. The more distant any two rings are, the less they tend to engage with one another directly.

Thus we end up with the edifice of public messaging, simplifications of scientific knowledge intended for people who will never spend much time delving into a field, and largely constructed by those who are not the most knowledgeable specialists in the field. Some of these simplifications are better than others, depending on the incentives of those creating them. It seems a necessary evil, given the way the world works. We all have the freedom to pursue a greater understanding in the aspects of life and technology that we consider important, but far from enough time to become a polymath. Some shortcuts are necessary in the service of doing some good in the world.

An aging essential 8: closing the gap between geroscience and the public it serves

Longevity medicine has reached an uncomfortable milestone: more clinically credible than at any prior point, and simultaneously more publicly confused. Senolytics, partial epigenetic reprogramming, and GLP-1 metabolic agents have entered human trials within a single decade. Alongside that progress, biological age tests, longevity clinics, and consumer wearables have scaled well ahead of any shared standard governing what they measure or what a person should do with the result. The field has begun to describe this as an implementation gap, in which biological age products and clinics operate ahead of validated standards and regulatory frameworks. The remedies under active discussion are directed at research and clinical infrastructure: standardizing what longevity clinics measure, how they are structured, and which biomarkers and outcomes should count. Few of them address the layer that ordinary people actually encounter, which is a number on an application, a panel of biomarkers, or a clinic promising rejuvenation, with no common framework against which any of it can be read.

The commercial layer is already substantial. Direct to consumer epigenetic age tests are now sold online, longevity clinics offering biological age panels have opened in many cities, and consumer wearables report readiness, recovery, and pace of aging scores derived from proprietary and largely undisclosed algorithms. None of these products share a common scale, none is obliged to demonstrate that its output responds to intervention, and a person who buys two of them may receive two different biological ages with no means of reconciling them. This is the environment into which any public facing instrument would arrive, and it is why such an instrument is worth building and not merely describing.

Cardiovascular medicine encountered a comparable problem and resolved it not with a new therapeutic but with a communication instrument: Life's Essential 8, which distilled a contested risk landscape into eight components scored from 0 to 100, and which has since been shown to track biological aging itself. This perspective argues that geroscience has assembled much of the material for an equivalent instrument, even while the field continues to disagree about foundational questions. Expert panels have converged on which biomarkers are worth tracking as outcomes in aging intervention trials, and have concluded that no single biomarker suffices, which leaves a composite as the only viable path. What has not happened is the translation of that research-level agreement into a public-facing instrument.